$XOS

Xos, Inc. (XOS): Submission of Matters to a Vote of Security Holders

Xos, Inc. (XOS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001819493 false 0001819493 2026-06-23 2026-06-23 0001819493 xos:CommonStockParValue0.0001PerShareMember 2026-06-23 2026-06-23 0001819493 xos:WarrantsEveryThirtyWarrantsExercisableForOneShareOfCommonStockAtExercisePriceOf345.00PerShareMember 2026-06-23 2026-06-23 UNITED STATE

Original reporting
Published Jun 25, 2026, 8:44 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$XOS
Neutral
medium confidence
Mentioned
$XOS
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$XOSNeutralLow
01

Why it matters

The most tradable elements are approvals that can enable future share issuance: (i) a 3,740,000-share increase to the 2021 Equity Incentive Plan and (ii) authorization for potential issuance of 20%+ of outstanding common stock in connection with certain convertible promissory notes (and related change-of-control approval).

02

Market read

This is a governance/authorization update; it can slightly shift dilution/financing expectations but provides no new operating or financial datapoints.

03

What to watch

The filing does not disclose the actual issuance timing or terms; any trading impact would depend on subsequent filings (e.g., prospectus/financing documents) rather than the vote results themselves.

Relevance 6/10Novelty 3/10Timing: after-hours/filing update following the June 23, 2026 annual meeting

Background

Xos, Inc. reported certified results from its June 23, 2026 virtual annual meeting, covering six proposals including director elections, auditor ratification, and equity/compensation matters.

Company-level read

Ticker impact

$XOSNeutralMedium confidence
Context

Xos filed an 8-K confirming stockholder votes on director elections, auditor ratification, and equity plan amendments at its June 23, 2026 annual meeting.

Expected impact

Likely limited near-term impact; any reaction would be small unless traders connect the approvals to imminent financing or dilution.

Evidence & confidence

The 8-K reports certified voting outcomes (no new financial guidance, deal, or enforcement action). The only potentially market-relevant items are the equity plan share increase and authorization for issuance of 20%+ of shares tied to convertible promissory notes, but the filing provides no pricing/terms beyond the vote.

Market effects

Minimal; governance and equity-plan approvals are company-specific and not a sector-wide catalyst.

Minimal; no regional macro or cross-listed event is described.

Minimal; no international transaction or regulatory action is mentioned.

Counterpoint

Traders may treat the convertible-note-related issuance authorization as a signal of potential near-term dilution/financing, which could matter more than the governance nature of the filing suggests.

Key entities

  • Xos, Inc.

    Nasdaq-listed issuer (XOS) reporting 8-K Item 5.07 with certified stockholder vote outcomes.

  • Grant Thornton LLP

    Ratified as independent auditor for fiscal year 2026 by stockholders.

Related articles

$AVGOMedAI 8/10

AVGO, CRWD, XOS, NVTS, FIVE: 5 Trending Stocks Today - Broadcom (NASDAQ:AVGO)

U.S. stocks fell Wednesday; the Dow slipped 1.2% and the S&P 500 fell 0.7%. Broadcom (AVGO) closed $479.23 (-0.49%); after-hours it dropped 13.78% after projecting Q3 revenue ~$29.4B and AI semiconductor revenue to exceed $16B. CrowdStrike (CRWD) fell 2.78% and raised FY2027 guidance; it also approved a 4-for-1 split. Navitas (NVTS) jumped 19.26% on an Nvidia MGX collaboration. Five Below (FIVE) rose 1.14% after Q1 results and raised FY outlook.

$XOSMedAI 9/10

XOS Stock Remains Red Hot As Company Bets On AI-Driven Energy Demand - Xos (NASDAQ:XOS)

Xos (NASDAQ:XOS) launched its Power Hub mobile energy storage system, designed to supply electricity to data-center and other sites within days instead of waiting years for U.S. grid connections, according to the company. The article cites IEA data-center electricity demand expected to nearly double by 2030. Xos reported Q ended March 2026 revenue of $11.23M (vs. $5.88M) and a $0.43/share loss vs. a $0.72 forecast.

$XOSMedAI 9/10

Xos Shares Are Surging Wednesday: What's Driving The Action? - Xos (NASDAQ:XOS)

Xos shares rose sharply on Wednesday, up 147.53% to $5.52, after a 220% after-hours jump Tuesday. The company said it launched its 2.5MWh Power Hub, a factory-integrated behind-the-meter energy storage system designed to enable “site energization within days” versus grid interconnection timelines of three to seven years. Traders cited IEA projections that data center electricity demand could roughly double by 2030.

$SKHYMed

SK Hynix’s $38 billion buildout has a name attached: Nvidia

SK Hynix (SKHY) approved about 54.3 trillion won (about $38.3B) for two memory plants through 2031, Reuters reported. About 35.2 trillion won funds a DRAM fab in Yongin (Y2) with construction starting July 2027 and first cleanroom June 2029. Remaining 19.1 trillion won supports a NAND plant in Cheongju. Reuters also said it is reviewing further shareholder returns.

$ITWMed

Illinois Tool Works Authorizes $6 Bln Buyback

Illinois Tool Works (ITW) said its board authorized a new share repurchase program of up to $6 billion. The board also approved a 7% increase in its regular annual cash dividend to $6.88 per share, effective with the Q4 dividend of $1.72 payable Oct. 9, 2026. ITW closed at $296.66 on Friday.

$JNJMed

Money talcs: Why J&J offered $5.5bn to end cancer cases

Johnson & Johnson is offering $5.5 billion to settle most of more than 70,000 pending talc-related cancer lawsuits, according to the company. Claims allege ovarian cancer or mesothelioma linked to asbestos-contaminated talc. J&J denies wrongdoing and says cases lack merit. Prior orders include $966m (LA) and $1.5bn (Baltimore), with appeals planned.